[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350143-105":59,"doc-detail-350143-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","osbpl3-drives-colorectal-cancer-progression-via-hippo-yap-signaling-and-modulates-mek-inhibitor-sensitivity","OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity","","Colorectal cancer progression depends on dysregulated signaling, yet upstream regulators of Hippo-YAP activity remain insufficiently defined. This study demonstrates that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to enhance tumor aggressiveness. Elevated OSBPL3 in clinical specimens correlates with reduced patient survival, and OSBPL3 depletion suppresses proliferation and invasion while inducing cell-cycle arrest. Mechanistically, OSBPL3 promotes YAP1 nuclear translocation through 14-3-3 binding, driving oncogenic transcription and contributing to MEK inhibitor resistance, which can be reversed by YAP1 suppression or combined YAP/MEK inhibition in organoids.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/osbpl3-drives-colorectal-cancer-progression-via-hippo-yap-signaling-and-modulates-mek-inhibitor-sensitivity/350143/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/osbpl3-drives-colorectal-cancer-progression-via-hippo-yap-signaling-and-modulates-mek-inhibitor-sensitivity/350143.png","ImageObject",300,407,{"name":92,"@type":93},"Riley West","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is OSBPL3’s role in Hippo-YAP signaling in colorectal cancer?","Question",{"text":112,"@type":113},"OSBPL3 modulates Hippo-YAP signaling by promoting YAP1 nuclear translocation. It binds 14-3-3 proteins to drive downstream oncogenic transcription.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does altering OSBPL3 expression affect colorectal cancer cell behavior?",{"text":117,"@type":113},"OSBPL3 depletion impairs cancer cell proliferation and invasion and induces cell-cycle arrest. OSBPL3 overexpression accelerates tumor growth.",{"name":119,"@type":110,"acceptedAnswer":120},"Why might tumors with high OSBPL3 expression resist MEK inhibitors, and how can resistance be overcome?",{"text":121,"@type":113},"High OSBPL3 expression is associated with resistance to MEK inhibitors. Resistance can be overcome by suppressing YAP1 or by combining YAP and MEK inhibition in patient-derived organoids.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350143,1790174477,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523885074,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","communications biology Article  \n\n| A Nature Portfolio journal |  | |\n| --- | --- | --- |\n| [https://doi.org/10.1038/s42003-026-09811-8](https://doi.org/10.1038/s42003-026-09811-8) |  |  |\n| OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity\u003Cbr> Check for updates |  |  |\n| Yuchen Zhong 1,2,5, Chaojing Zheng3,4,5, Zitong Wang2,3,5, Weiyuan Zhang2, Hongyu Wu3, Jun Luo2,3, Hao Zhang2, Chunlin Wang2, Chenkai Zhang 2, Hanqing Hu2, Ziming Yuan2, Meng Wang3,\u003Cbr>Qian Zhang 3  & Guiyu Wang 2  |  |  |\n| Colorectal cancer progression involves dysregulated signaling pathways such as Hippo-YAP, but upstream regulators remain poorly deﬁned. Here we demonstrate that oxysterol-binding protein-like 3 (OSBPL3) modulates Hippo-YAP signaling to drive tumor aggressiveness. Analysis of clinical specimens and experimental models shows that elevated OSBPL3 levels in colorectal cancer tissues correlate with shortened patient survival. Depleting OSBPL3 impairs cancer cell proliferation and invasion and induces cell cycle arrest, while its overexpression accelerates tumor growth. Mechanistic studies reveal that OSBPL3 binds 14-3-3 proteins to promote YAP1 nuclear translocation, activating downstream oncogenic pathways. Notably, tumors with high OSBPL3 expression exhibit resistance to MEK inhibitors, but this resistance is overcome by YAP1 suppression or combined YAP/MEK inhibition in patient-derived organoids. These results establish OSBPL3 as a critical Hippo-YAP pathway regulator and propose targeting OSBPL3-mediated signaling as a therapeutic strategy for colorectal cancers with Hippo pathway alterations. |  |  |\n| Colorectal cancer (CRC) is a prevalent malignancy of the digestive tract. As of 2023, statistics indicate that CRC is the second most common cause of cancer-related deaths in the United States, with approximately 153,020 individuals diagnosed and 52,550 succumbing to the disease annually1. The Yes1-Associated Protein (YAP1), a critical effector of the Hippo pathway, plays a signiﬁcant role in various cancers, including CRC. Its translocation into the nucleus and subsequent association with the TEAD family promote transcription, thereby enhancing its oncogenic potential. Prior studies demonstrate that both overexpression and knockdown of YAP1 can impact CRC proliferation, invasion, and metastasis phenotypes2–4. In CRC, YAP1 hyperactivation promotes cancer stemness, epithelial-mesenchymal transition, and chemoresistance. Beyond CRC, YAP1 is widely regarded as anoncogenic factor in many other tumor types5,6. However, the upstream mechanisms driving YAP1 dysregulation in CRC are incompletely understood, particularly those involving lipid-metabolism-related proteins.\u003Cbr>Oxysterol-binding protein-like 3 (OSBPL3), a member of theoxysterol-binding protein family, has recently gained attention for its dual role in lipid homeostasis and cancer progression. Previous research | identiﬁes OSBPL3 as an intracellular lipid receptor involved in the regulation of cell adhesion and organization of the actin cytoskeleton7. Studies indicate a trend of overexpression of OSBPL3 in CRC and establish it as an independent prognostic risk factor through immunohistochemistry8. Similar ﬁndings in liver, lung, and pancreatic cancers suggest a prooncogenic role for OSBPL39–11. Another study in gastric cancer explores the molecular biology of OSBPL3, revealing that its knockdown leads to reduced proliferation and impacts the cell cycle in gastric cancer12. While OSBPL3 overexpression has been associated with poor prognosis in other cancers, its functional signiﬁcance in CRC remains unexplored. The speciﬁc function and role of OSBPL3 in CRC remain elusive, yet our study uncovers its regulatory effect on the expression and subcellular localization of YAP1 in CRC.\u003Cbr>MEK inhibitors, targeting the MAPK (Mitogen-Activated Protein Kinase) pathway, play a crucial role in numerous biological processes, including cell grow","cbCaivxCKDT3fkbh","https://ap.wps.com/l/cbCaivxCKDT3fkbh","pdf",11443803,"English","# Background and rationale\n## Hippo-YAP signaling in colorectal cancer\n## MEK inhibitors and therapeutic resistance\n# OSBPL3 as an upstream regulator\n## Clinical correlation with patient outcomes\n## Effects of OSBPL3 depletion or overexpression\n# Mechanistic basis\n## OSBPL3 binding to 14-3-3 and YAP1 nuclear translocation\n## Downstream oncogenic activation\n# Therapeutic implications\n## OSBPL3-associated MEK inhibitor resistance\n## Overcoming resistance via YAP1 suppression or combined inhibition","[{\"question\":\"What is OSBPL3’s role in Hippo-YAP signaling in colorectal cancer?\",\"answer\":\"OSBPL3 modulates Hippo-YAP signaling by promoting YAP1 nuclear translocation. It binds 14-3-3 proteins to drive downstream oncogenic transcription.\"},{\"question\":\"How does altering OSBPL3 expression affect colorectal cancer cell behavior?\",\"answer\":\"OSBPL3 depletion impairs cancer cell proliferation and invasion and induces cell-cycle arrest. OSBPL3 overexpression accelerates tumor growth.\"},{\"question\":\"Why might tumors with high OSBPL3 expression resist MEK inhibitors, and how can resistance be overcome?\",\"answer\":\"High OSBPL3 expression is associated with resistance to MEK inhibitors. Resistance can be overcome by suppressing YAP1 or by combining YAP and MEK inhibition in patient-derived organoids.\"}]","OSBPL3 drives colorectal cancer progression via Hippo-YAP signaling and modulates MEK inhibitor sensitivity | PDF",1790087371,48,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba975f5750ac5ed44642a7a0c1a38231.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/05a2d278a5ea5aaa30e3e8fd1997bec9.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9379da03f9730ce00ce472531b964332.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ed7aa5b9bbd43076d39ce2dd784e182.webp",980,1301]